Radiopharm Theranostics Q3 2024 Highlights: Clinical Milestones, Leadership Expansion, and Strategic Growth

Radiopharm Theranostics (ASX: RAD) announced significant progress and updates for the quarter that concluded on 30 September 2024. The company achieved a milestone by dosing its first patient in the Phase 1 trial for RAD204, targeting Non-Small Cell Lung Cancer. Additionally, the U.S. FDA granted IND approval for the Phase 2b trial of RAD101, focused on treating brain metastases. Strengthening its leadership, Dr. Dimitris Voliotis joined as the new Chief Medical Officer.

 Radiopharm also increased its stake in Radiopharm Ventures to 75%, demonstrating a strategic investment in its subsidiary. Furthermore, the company launched an American Depositary Receipt (ADR) program to enhance its international market presence and attract global investors. These advancements position Radiopharm for continued growth and progress in the radiopharmaceutical space.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com